CD52 and Autoimmunity: Based on these observations, we propose that both the predominance of immature B cells expressing low levels of CD52 during the rapid reconstitution of the B cell compartment following treatment, as well as the sequestration of soluble CD52 by therapeutic antibody induce a homeostatic imbalance that promotes breaks in B cell tolerance that in turn drive secondary autoimmunity (59).